AKAvni Kaya

Avni Kaya

*This is an algorithmically generated author record based on publicly available information.

Avni Kaya has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Relationship of Serum Sex-Hormone Binding Protein and Free Androgen Index Levels to Newborn’s Breast Enlargement

    by Avni Kaya, Abdullah Erdil, Zerrin Orbak

    Aim This study aimed to analyze body mass index, estrogen, testosterone, sex-hormone-binding-globulin (SHBG), free androgenic index (FAI), and estrogen/testosterone ratio and their relationship to breast enlargement in newborns. Additionally, we defined the mean, minimum, maximum, standard deviation, and percentiles of SHBG and FAI in 14-28 days-old babies. Methods Forty babies with breast enlargement aged 14-28 days (17 boys and 23 girls) were included in the study. As controls were taken 36 babies in the same age group (19 boys and 17 girls). The SHBG and FAI values were calculate as mean, minimum, maximum, standard deviation, and percentages in 14-28 days-old newborns. Normal values and 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles of the SHBG and FAI values were calculated according to sex. Results The mean, standard deviation, minimum, and maximum SHBG values among girls, boys, and all participants were 74.84±26.21 ng/dL (26.80-135.20 ng/dL), 73.22±24.98 ng/dL (13.00-144.80 ng/dL), and 74.07±25.48 ng/dL (13.00-144.80 ng/dL), respectively. The mean, standard deviation, minimum, and maximum FAI values of girls, boys, and all participants were 0.44±0.33 (0.03-1.38), 1.42±0.54 (0.69-3.46), and 0.91±0.66 (0.03-3.46), respectively. Conclusion Neonatal breast enlargement is not associated with weight, length, body mass index, estrogen, testosterone, SHBG, FAI, Estrogen/Testosterone ratio, or sex. In the physiology of neonatal breast enlargement, there are still situations that await clarification.

  • Open Access

    Sirolimus-Induced Hepatitis in Two Patients with Hyperinsulinemic Hypoglycemia

    by Belma Haliloğlu, Heybet Tüzün, Sarah E. Flanagan, Muhittin Çelik, Avni Kaya, Sian Ellard, Mehmet Nuri Özbek

    Sirolimus has been reported to be effective in the treatment of the diffuse form of congenital hyperinsulinism (CHI), unresponsive to diazoxide and octreotide, without causing severe side effects. Two newborns with CHI due to homozygous ABCC8 gene mutations were started on sirolimus aged 21 and 17 days, due to lack of response to medical treatment. A good response to sirolimus was observed. At follow-up after ten and two months of treatment, liver enzymes were found to be increased [serum sirolimus level 1.4 ng/mL (normal range: 5-15), aspartate aminotransferase (AST): 298U/L, alanine aminotransferase (ALT): 302U/L and serum sirolimus level: 9.9 ng/mL, AST: 261U/L, ALT: 275U/L, respectively]. In Case 1, discontinuation of the drug resulted in normalization of liver enzymes within three days. Two days after normalization, sirolimus was restarted at a lower dose, which resulted in a repeated increase in transferases. In Case 2, a reduction of sirolimus dose caused normalization of liver enzymes within ten days. When the dose was increased, enzymes increased within three days. Sirolimus was discontinued in both cases. The rapid normalization of liver enzyme levels after sirolimus withdrawal or dose reduction; elevation of transaminases after restart or dose increase and rapid normalization after sirolimus withdrawal were findings strongly suggestive of sirolimus-induced hepatitis. To the best of our knowledge, this is the first report of sirolimus-induced hepatitis in CHI. Sirolimus is a promising drug for CHI patients who are unresponsive to medical treatment, but physicians should be vigilant for adverse effects on liver function.


  • Plasma Kisspeptin Levels in Hypothyroidism and Premature Newborns

    by A Kaya, Z Orbak, H Polat, E Şebin, İ Polat, E Gülfidan

    Aim: The purpose of this study was to determine kisspeptin levels in healthy newborns and to show whether there is significant difference kisspeptin levels between males and females in hypothyroid newborns and healthy term newborns.

  • Leptin and neuropeptide Y levels in newborns

    by Avni Kaya, Zerrin Orbak, İsMail Polat, Harun Polat, Musa Gümüşdere

    Aim: Several studies have investigated leptin and neuropeptide Y (NPY) levels in children, but the information for newborns in the literature is limited. The purpose of this study was to determine leptin and NPY levels in 14- to 28-day-old newborns. Materials and methods: This prospective study was performed in Atatürk University Medical Faculty Research Hospital Neonatal Clinic, Erzurum, Turkey between July and December, 2014. Sixty-two 14- to 28-day-old neonates, 26 female and 36 male, were included. Age, height, and body weight of the patients were recorded. Feeding status was also recorded. The newborns were divided into two groups – those receiving breastfeeding only and those receiving breastfeeding and formula. Plasma leptin levels were measured using enzyme amplified sensitivity immunoassay (EASIA). Results: The mean leptin level in 14- to 28-day-old female neonates was 4.25±3.08 ng/mL, and the mean NPY level was 24.79±9.87 ng/mL. The mean leptin level in 14- to 28-day male neonates was 3.49±2.52 ng/mL, and the mean NPY level was 25.80±9.58 ng/mL. No significant difference was determined between leptin (p=0.228) or NPY (p=0.144) in terms of feeding status. No significant difference was also observed between the sex in terms of leptin or NPY levels (leptin p=0.775 and NPY p=0.687). Conclusion: There were no differences in terms of feeding status and sex in leptin and NPY levels in the neonatal period.


  • Open Access

    Plasma Kisspeptin Levels in Newborn Infants with Breast Enlargement

    by Avni Kaya, Zerrin Orbak, Harun Polat, Atilla Çayır, Abdullah Erdil, Hakan Döneray

    Objective: Kisspeptin levels have been reported in children with premature thelarche, precocious puberty and adolescent gynecomastia, but there are no reports on kisspeptin levels in the neonatal period. This study aimed to investigate plasma kisspeptin hormone levels in newborns with and without breast enlargement. Methods: Plasma kisspeptin levels and other related biochemical variables were investigated in this prospective study conducted on 40 (20 girls and 20 boys) newborn infants with breast enlargement and on 40 healthy control infants (20 girls and 20 boys). Two-milliliter venous blood samples were taken in hemogram tubes with K2EDTA. Kisspeptin assays were performed using the enzyme-immunoassay method. Results: Mean plasma kisspeptin levels were 0.6 +/- 0.2 ng/mL in the study group and 0.5 +/- 0.2 ng/mL in the control group. Plasma kisspeptin concentrations were significantly higher in the study group (p=0.039) and also showed a correlation with serum prolactin levels (p=0.006). Significant correlations were also determined between plasma kisspeptin and luteinizing hormone concentrations (p=0.05, r=0.312). Conclusion: The findings of this study suggest that plasma kisspeptin and serum prolactin levels may be involved in the physiopathology of breast enlargement in newborns.


  • Ewing's Sarcoma Localized in the Mandible: A Case Report

    by S Akbayram, M Başaranoglu, A Kaya, M Açıkgöz, L Üstyol, GA Taşkın, M Dogan

    Ewing's sarcoma is one of the most aggressive primary bone tumours. Ewing's sarcoma arising from the bones of the head and neck region is extremely rare only four to nine per cent of all Ewing's sarcoma originate in the head and neck region. We report a case of Ewing's sarcoma localized in the mandible because of its unusual presentation.


  • Effect of Kidney Transplantation on Smoking Habits of Kidney Donors

    by M. Keles, U. Avsar, Z. Avsar, H. Emre, E. Cankaya, Z. Cansever, A. Kaya, O. Topdagi, A. Uyanik, B. Aydinli


  • Intracranial Hemorrhage in a Patient Diagnosed with Idiopathic Thrombocytopenic Purpura and Diabetic Ketoacidosis

    by B Özkan, A Kaya, A Erdil, Mi Turan, M Büyükavcı, H Tan

    The Editor, Sir, A 15-year old girl presented with rapid respiration and excessive water consumption and urine production. At physical examination, her general condition was average, and she was lucid, oriented and cooperative. Respiratory acidosis was present.

  • An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D

    by A Kaya

    Aim: Leuprolide acetate is a gonadotropin releasing hormone analogue frequently used in the treatment of central precocious puberty. Research is currently taking place into its effects on endocrine systems. To investigate the effect of leuprolide acetate on Vitamin D and bone mineral density.


  • Comparison of Cerebral Oximeter and Pulse Oximeter Values in the first 72 hours in Premature, Asphyctic and Healthy Newborns

    by A Kaya, M Okur, E Sal, E Peker, M Köstü, O Tuncer, E Kırımi

    The monitoring of oxygenation is essential for providing patient safety and optimal results. We aimed to determine brain oxygen saturation values in heatlhy, asphyctic and premature newborns and to compare cerebral oximeter and pulse oximeter values in the first 72 hours of life in neonatal intensive care units.This study was conducted at the neonatal intensive care unit (NICU) of Van Yüzücü Yil University Research and Administration Hospital. Seventy-five neonatal infants were included the study (28 asphyxia, 24 premature and 23 mature healty infants for control group). All infants were studied within the first 72 hours of life. We used a Somanetics 5100C cerebral oximeter (Invos oximeter cerebral/somatic, Troy, MI, USA). The oxygen saturation information was collected by a Nellcor N-560 pulse oximeter (Nellcor-Puriton Bennet Inc, Pleasanton, CA, USA).In the asphyxia group, the cerebral oximeter average was 76.85 ± 14.1, the pulse oximeter average was 91.86 ± 5.9 and the heart rate average was 139.91 ± 22.3. Among the premature group, the cerebral oximeter average was 79.08 ± 9.04, the pulse oximeter average was 92.01 ± 5.3 and the heart rate average was 135.35 ± 17.03. In the control group, the cerebral oximeter average was 77.56 ± 7.6, the pulse oximeter average was 92.82 ± 3.8 and the heart rate average was 127.04 ± 19.7.Cerebral oximeter is a promising modality in bedside monitoring in neonatal intensive care units. It is complementary to pulse oximeter. It may be used routinely in neonatal intensive care units.